Management of Recurrent Vulvo-Vaginal Candidosis as a Chronic Illness

Femicare, Clinical Research for Women, Tienen, Belgium. gilbert.donders @
Gynecologic and Obstetric Investigation (Impact Factor: 1.7). 10/2010; 70(4):306-21. DOI: 10.1159/000314022
Source: PubMed


For sporadic acute Candida vaginitis, any oral or local antifungal therapy can be used. For women with recurrent vulvo-vaginal candidosis (RVC), on the other hand, such simple approaches are insufficient, regardless of the product chosen. Instead, RVC should be managed as any other chronic disease and requires long-term, prophylactic, suppressive antifungal treatment. A regimen using individualized, decreasing doses of oral fluconazole (the ReCiDiF regimen) was proven to be highly efficient and offered great comfort to the patients. During this regimen, it is crucial that patients are carefully examined by anamnestic, clinical, microscopic and culture-proven absence of Candida. If a relapse occurs, the medication is adjusted and efforts are taken to find a possible triggering factor for the reactivation of the infection. Care has to be taken not to accumulate 'don't do's', unless the efficiency of a measure has been proven, by trying to eliminate one risk factor at a time for 2 months. Known possible triggers to be kept in mind are (1) antibiotic use, (2) use of specific contraceptives, especially combined contraceptive pills, (3) disturbed glucose metabolism, (4) the use of personal hygienic products, and (5) tight clothing or plastic panty liners. In therapy-resistant cases, non-albicans infection must be ruled out, and alternative therapies should be tried. Boric acid is proven to be efficient in most of these resistant cases, but other non-azoles like amphotericin B, flucytosine, gentian violet, and even caspofungin may have to be tried. As a final remark it has to be said that many patients feel poorly understood and inefficiently managed by many care-givers, increasing their feelings of guilt and sexual inferiority. Therefore, attention has to be given to take the disease seriously, follow strict treatment regimens, and advise precisely and based on individual evidence concerning any possible risk factors for recurrence. In case of therapy-resistant vulvo-vaginitis, reconsider your diagnosis and/or consider referral to specialized therapists.

1 Follower
26 Reads
  • Source
    • "Recurrent vulvovaginal candidosis (RVVC) is a debilitating chronic infectious condition. It is defined as four or more acute inflammatory episodes of VulvoVaginal Candidosis (VVC), also known as vaginal yeast infection, within a year [1,2]. The prevalence of RVVC is estimated at 6-8% in women aged between 18 and 65 years in the USA and Western Europe, according to two large studies [3,4] and similar estimates can be derived from assessments of RVVC prevalence as proportion of VVC cases and studies on population-based VVC prevalence [3-8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recurrent vulvovaginal candidosis (RVVC) is a chronic condition causing discomfort and pain. Health status and health-related quality of life (HRQoL) in RVVC were never previously described using validated questionnaires. The objective of this study is to describe subjective health status and HRQoL and estimate health state utilities among women with RVVC. A cross-sectional online survey was conducted among women who reported having suffered four or more yeast infections over the past 12 months, in five European countries (France, Germany, Italy, Spain and the UK) and the USA. Index scores were derived from the EQ-5D, a questionnaire providing a single index value for health status. The SF-36 questionnaire was used for HRQoL assessment. Information on disease severity, treatment patterns and productivity was also collected. 12,834 members of online research panels were contacted. Among them, 620 women with RVVC (5%) were selected to complete the full questionnaire. The mean EQ-5D index score was 0.70 (95% confidence interval: [0.67, 0.72]) and the difference between women with a yeast infection at the time of questionnaire completion and other respondents was 0.05 (p = 0.47). The EQ-5D index score increased significantly with the time since last infection (p < 0.001). 68% of women reported depression/anxiety problems during acute episode, and 54% outside episodes, compared to less than 20% in general population (p < 0.001). All SF-36 domain scores were significantly below general population norms. Mental health domains were the most affected. The impact on productivity was estimated at 33 lost work hours per year on average, corresponding to estimated costs between [euro sign]266/year and [euro sign]1,130/year depending on the country. Subjective health status and HRQoL during and in between acute inflammatory episodes in women with RVVC are significantly worse than in the general population, despite the use of antifungal therapy. The average index score in women with RVVC is comparable to other diseases such as asthma or COPD and worse than diseases such as headache/migraine according to US and UK catalogs of index scores. The survey also revealed a significant loss of productivity associated with RVVC.
    Health and Quality of Life Outcomes 10/2013; 11(1):169. DOI:10.1186/1477-7525-11-169 · 2.12 Impact Factor
  • Source
    • "Despite RVVC being considered a Candida infection that is more dependent on the host characteristics, therapeutics approaches available and able to allow a remission of the symptoms between episodes are antifungal drugs used for a long period of time [8] [9] [11]. Some authors consider that new therapeutic strategies must be considered for RVVC control [3] [9] [10]. In addition to the limited number of available antifungal drugs, the restrictions to its use stress the need for the development and validation of new therapeutic strategies exhibiting distinct mechanisms of action and/or evasion of resistance [12] [13] [14] [15]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this work was to study the anti-Candida activity of lidocaine and nitroglycerin alone and in combination. Ten Candida strains were included, corresponding to 1 collection type strain (ATCC 10231) and 9 clinical isolates: 4 C. albicans, 2 C. glabrata, 1 C. tropicalis, 1 C. krusei, and 1 C. parapsilosis. The CLSI reference M27-A3 micromethod was used to determine the anti-Candida activity of the drugs alone; minimal inhibitory and lethal concentrations were determined. The classic checkboard technique was used to determine the activity of combined drugs. Lidocaine fungicidal effect was dosedependent. Nitroglycerin exhibited a higher effect. The drugs combination resulted in a reduction of the inhibitory concentration, corresponding to an additive effect. In conclusion, both drugs exhibited an interesting anti-Candida activity. The combination of lidocaine with nitroglycerin was shown to have an additive effect against Candida spp., predicting the interest to include, in the future, these drugs in a new delivery system for the treatment of mucocutaneous candidosis.
    Infectious Diseases in Obstetrics and Gynecology 05/2012; 2012(1):727248. DOI:10.1155/2012/727248
  • Source
    BMJ (online) 11/2011; 343(7834):d7314. DOI:10.1136/bmj.d7314 · 17.45 Impact Factor
Show more